348 A phase II trial of docetaxel in patients (PTS) with anthracycline resistant (AR) metastatic breast cancer (MBC)

Guastalla, Jean‐Paul; Bonneterre, Jacques; Fumoleau, P.; Piccart, Martine; Tubiana, M.; Chevallier, B; Nieamann, C.; Alakl, May; Nichol, A.; Riva, A.; Marty, M.

doi:10.1016/0959-8049(95)95601-2

Cited by 8 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12,13 in patients with MBC with response rates of 29-50% in anthracycline-resistant disease. [14][15][16] Here, we report on the mobilisation of CD34 ϩ cells with docetaxel, and examined the ability of these cells to support multiple cycles of HDT.…”

mentioning

confidence: 99%

Docetaxel effectively mobilizes peripheral blood CD34+ cells

Prince

Toner

Seymour

et al. 2000

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:We prospectively evaluated docetaxel (100 mg/m 2 ) with G-CSF (10 g/kg S.C., daily) for mobilization efficiency in 26 patients with breast cancer. The minimum target yield was Ͼ4.5 ؋ 10 6 CD34 ؉ cells/kg (optimum = 9 ؋ 10 6 /kg), sufficient to support the subsequent three cycles of high-dose therapy (HDT). The peak days for peripheral blood (PB) CD34؉ cells were day 8 and day 9. Seven collections began on day 7, 16 on day 8 and three on day 9. The median peripheral blood progenitor cell (

show abstract

mentioning

confidence: 99%

Docetaxel effectively mobilizes peripheral blood CD34+ cells

Prince

Toner

Seymour

et al. 2000

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…In a series of three phase II studies in first-line treatment of metastatic breast cancer, an overall response rate of 56% was seen in 117 patients [Fumoleau et al 1996;Hudis et al 1996;Trudeau et al 1996]. In a similar number of second-line patients, the response rate was 49% [Ravdin et al 1995;Ravdin 1996;ten Bokkel Huinink et al 1994;Valero et al 1995] and, of note, was 42% in the 105 patients defined as anthracycline-resistant [Guastalla et al 1995;Ravdin et al 1995;Ravdin 1996;Valero et al 1995].…”

Section: Introductionmentioning

confidence: 91%

Interaction between Herceptin<sup>®</sup> and Taxanes

Dièras¹,

Beuzeboc²,

Laurence³

et al. 2001

Oncology

View full text Add to dashboard Cite

The taxanes and Herceptin^® have been shown to possess significant clinical activity in metastatic breast cancer. Preclinical testing of taxane/Herceptin combinations demonstrated additive and synergistic interactions with paclitaxel and docetaxel, respectively. In a pivotal clinical trial, combination of paclitaxel (3-weekly) and Herceptin was associated with an increased response rate compared with paclitaxel monotherapy (41% vs. 17%; p = 0.001). The combination therapy also significantly improved time to disease progression (6.9 vs. 2.7 months; p < 0.05). In a phase II study of weekly paclitaxel plus Herceptin in patients with normal or increased tumor HER2 levels, a response was observed in 60% of patients and the regimen was well tolerated. Responses were more frequent in patients with HER2-overexpressing tumors (83% vs. 45%). Preliminary results from a phase II study of Herceptin plus docetaxel in patients with HER2-overexpressing tumors indicate significant activity, with a response observed in 7 (44%) of 16 evaluable patients. The preliminary results of a trial of weekly docetaxel and Herceptin demonstrate a response rate of 54% in 13 evaluable patients. Additional European trials of Hercep- tin/taxane combinations as first- and second-line and adjuvant therapy are ongoing. The results of the studies to date indicate that regimens combining Herceptin with 3-weekly and weekly taxane are effective and well tolerated.

show abstract

Taxotère® en deuxième ligne dans le cancer du sein métastatique

Culine¹

1999

La Revue de Médecine Interne

View full text Add to dashboard Cite

348 A phase II trial of docetaxel in patients (PTS) with anthracycline resistant (AR) metastatic breast cancer (MBC)

Cited by 8 publications

References 0 publications

Docetaxel effectively mobilizes peripheral blood CD34+ cells

Docetaxel effectively mobilizes peripheral blood CD34+ cells

Interaction between Herceptin<sup>®</sup> and Taxanes

Taxotère® en deuxième ligne dans le cancer du sein métastatique

Contact Info

Product

Resources

About